Combination of syrosingopine and mitochondrial inhibitors for the treatment of cancer and immunosuppression
US8993587B2 · kind B2 · utility
1Cited by
0References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 9, 2012 |
| Grant date | Mar 31, 2015 |
| Priority date | — |
| Expiry date | Jan 11, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a combination of syrosingopine and a mitochondrial inhibitor, e.g. metformin or oligomycin, and the use of the combination of syrosingopine and a mitochondrial inhibitor for the treatment of cancer and for achieving immunosuppression. The invention also relates to a fluorescence-based method for predicting syrosingopine sensitivity of a cancer cell.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.